The EVARREST® Fibrin Sealant Patch Liver Study
Public ClinicalTrials.gov record NCT01993888. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST® Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Study identification
- NCT ID
- NCT01993888
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- EVARREST® Fibrin Sealant Patch Biological
- Standard of Care (SoC) Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2013 (Type not available)
- Primary completion
- Jul 2014 (Actual)
- Completion
- Sep 2014 (Actual)
- Last update posted
- Jul 11, 2016
2013 – 2014
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Investigation Site #13 | Birmingham | Alabama | 35294 | — |
| Clinical Investigation Site #10 | Augusta | Georgia | 30912 | — |
| Clinical Investigation Site #16 | Chicago | Illinois | 60611 | — |
| Clinical Investigation Site #12 | Chicago | Illinois | 60637 | — |
| Clinical Investigation Site #15 | New Orleans | Louisiana | 70121 | — |
| Clinical Investigation Site #9 | St Louis | Missouri | 63110 | — |
| Clinical Investigation Site #11 | New York | New York | 10032 | — |
| Clinical Investigation Site #14 | New York | New York | 10065 | — |
| Clinical Investigation Site #8 | Philadelphia | Pennsylvania | 19107 | — |
| Clinical Investigation Site #17 | Pittsburgh | Pennsylvania | 15213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01993888, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2016 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01993888 live on ClinicalTrials.gov.